Loading
HNRNPU (Heterogeneous nuclear ribonucleoprotein U) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Burkitt lymphoma.
DNA- and RNA-binding protein involved in several cellular processes such as nuclear chromatin organisation, telomere-length regulation, transcription, mRNA alternative splicing and stability, Xist-mediated transcriptional silencing and mitotic cell progression. Plays a role in the regulation of interphase large-scale gene-rich chromatin organisation through chromatin-associated RNAs (caRNAs) in a transcription-dependent manner, and thereby maintains genomic stability. Required for the localisation of the long non-coding Xist RNA on the inactive chromosome X (Xi) and the subsequent initiation and maintenance of X-linked transcriptional gene silencing during X-inactivation.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant.
In plain words · HNRNPU (Heterogeneous nuclear ribonucleoprotein U) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Burkitt lymphoma.
HNRNPU (Heterogeneous nuclear ribonucleoprotein U) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Burkitt lymphoma.
DNA- and RNA-binding protein involved in several cellular processes such as nuclear chromatin organisation, telomere-length regulation, transcription, mRNA alternative splicing and stability, Xist-mediated transcriptional silencing and mitotic cell progression.
No product in this corpus aims at HNRNPU yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
Broadly expressed or essential: HPA lists HNRNPU among essential proteins and finds the RNA at low tissue specificity; a medicine acting on the wild-type protein would expose normal tissue too. HPA HNRNPU: RNA low tissue specificity; high antibody staining in 41 normal tissues; highest cancer staining cervical cancer (11 of 11 high). Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Lymphoma); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 7 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas HNRNPU tissue; Open Targets ENSG00000153187 associations
First described 1992. Earliest sequence paper UniProt cites for the protein: Kiledjian et al, EMBO J, 1992, "Primary structure and binding activity of the hnRNP U protein: binding RNA through RGG box". Source.
Sources: HGNC HGNC:5048 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q00839 (protein name, function text, keywords and locations (REST API)); CIViC gene HNRNPU (1 evidence items, 0 assertions, 1 variants; diseases: Burkitt Lymphoma (GraphQL API, CC0))
DNA- and RNA-binding protein involved in several cellular processes such as nuclear chromatin organisation, telomere-length regulation, transcription, mRNA alternative splicing and stability, Xist-mediated transcriptional silencing and mitotic cell progression. Plays a role in the regulation of interphase large-scale gene-rich chromatin organisation through chromatin-associated RNAs (caRNAs) in a transcription-dependent manner, and thereby maintains genomic stability. Required for the localisation of the long non-coding Xist RNA on the inactive chromosome X (Xi) and the subsequent initiation and maintenance of X-linked transcriptional gene silencing during X-inactivation. Plays a role as a RNA polymerase II (Pol II) holoenzyme transcription regulator. Promotes transcription initiation by direct association with the core-TFIIH basal transcription factor complex for the assembly of a functional pre-initiation complex with Pol II in a actin-dependent manner. Blocks Pol II transcription elongation activity by inhibiting the C-terminal domain (CTD) phosphorylation of Pol II and dissociates from Pol II pre-initiation complex prior to productive transcription elongation. Location: Nucleus; Nucleus matrix; Chromosome; Nucleus speckle (UniProt). Locus 1q44 (HGNC).
RNA: low tissue specificity, detected in all normal tissues.
Medium: Adipose tissue, Liver, Ovary, Parathyroid gland.
Medium only: lymphoma.
HPA HNRNPU tissue · HPA HNRNPU pathology · HPA protein class: Essential proteins
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"HNRNPU" OR ABSTRACT:"HNRNPU" OR TITLE:"heterogeneous nuclear ribonucleoprotein U" OR ABSTRACT:"heterogeneous nuclear ribonucleoprotein U" OR TITLE:"Heterogeneous nuclear ribonucleoprotein U" OR ABSTRACT:"Heterogeneous nuclear ribonucleoprotein U" OR TITLE:"SAF-A" OR ABSTRACT:"SAF-A" OR TITLE:"FLJ37978" OR ABSTRACT:"FLJ37978" OR TITLE:"FLJ30202" OR ABSTRACT:"FLJ30202") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about HNRNPU, not a curated reading list.
Shares Burkitt lymphoma, CIViC.
Shares Burkitt lymphoma, CIViC.
Shares Burkitt lymphoma, CIViC.
Shares Burkitt lymphoma, CIViC.
Shares Burkitt lymphoma, CIViC.
Shares Burkitt lymphoma, CIViC.
Shares Burkitt lymphoma, CIViC.
Shares Burkitt lymphoma, CIViC.